Table 1.

Clinical characteristics of patients with NSCLC harboring EGFR kinase fusions

Patient no.AgeGenderEthnicityDiagnosisSmoking statusSites of diseasePrior treatmentEGFR fusionEGFR TKIBest responseDuration of EGFR TKI therapy
135FemaleSouth AsianStage IV lung adenocarcinomaNeverLung- RT to the whole brain and T8 vertebraEGFR–RAD51ErlotinibPR8 months
Lymph nodes
Bone
Brain
Adrenal gland
Breast
Peritoneum
Eye
221FemaleCaucasianStage IV lung adenocarcinoma3 pack yearsLung- RT to the thoracic spineEGFR–RAD51ErlotinibPR5 months
Lymph nodes- Radiosurgery to brain mets
Bone- RT to the right hip
Brain
343FemaleCaucasianStage IV lung adenocarcinoma10 pack years, quit > 10 years agoLung- WBIEGFR–PURBErlotinibPR20 months, ongoing
Bone- Carboplatin, pemetrexed, bevacizumab, 6 cycles
Brain
438MaleCaucasianStage IV lung adenocarcinomaFormer light smoker (3 pack years)Lung- Cisplatin/pemetrexed, 6 cyclesEGFR–RAD51ErlotinibPR6 months, ongoing
Lymph nodes- Maintenance pemetrexed, 11 cycles
Pleura
Bone
560FemaleCaucasianStage IV lung adenocarcinomaNeverLung- Craniotomy- RT to surgical bedEGFR–RAD51N/AN/AN/A
Lymph nodes- Carboplatin/pemetrexed, 4 cycles
Brain- Maintenance pemetrexed, 6 cycles
  • Abbreviations: RT, radiation therapy; WBI, whole-brain irradiation; PR, partial response; N/A, not applicable; Mets, metastases.